Skip to content

Study · Observational study · n = 7 · 1989

3 results

Comparison of growth hormone releasing hormone therapy and growth hormone therapy in growth hormone deficiency.

Butenandt O, Staudt B

European journal of pediatrics1 Feb 1989Cited by 5 (Europe PMC)

PMID2537727 (opens in a new tab)DOI10.1007/bf00595894 (opens in a new tab)PepBankPUB-02537727
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In seven children with GH deficiency of hypothalamic origin, an intravenous GHRH(1-29)-NH2 bolus raised serum GH by a mean of 10.7 ng/ml.

    In plain wordsIn seven children with growth hormone deficiency, a GHRH injection into a vein raised growth hormone.

    Peptide
    Sermorelin
    Outcome
    IncreaseSerum GH increase after GHRH i.v. bolus
    Study

    n = 7

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Mean serum GH increase
    10.7 ng/ml
    i.v. bolus GHRH
    Serum GH increase range
    2.5 to 29.3 ng/ml
    i.v. bolus GHRH

    Source sentences

    Summary
    Seven children with growth hormone deficiency of hypothalamic origin responded to an i.v. bolus of growth hormone releasing hormone (GHRH) (1-29)-NH2 with a mean serum increase of 10.7 ng/ml growth hormone (GH) (range 2.5-29.3 ng/ml).
  2. 02HumanObservational studyEfficacy outcome

    In five of seven children with GH deficiency, continuous subcutaneous GHRH for at least 6 months did not improve the growth rate.

    In plain wordsIn five of seven children with growth hormone deficiency, months of GHRH injections under the skin did not improve growth.

    Peptide
    Sermorelin
    Outcome
    No significant changeGrowth rate on continuous s.c. GHRH (no improvement)
    Study

    n = 5

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4-6 micrograms/kg twice daily · subcutaneous · at least 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Continuous s.c. administration of GHRH of 4-6 micrograms/kg twice daily for at least 6 months did not improve the growth rate in five of the patients.
    1 context sentence
    Summary · context
    Seven children with growth hormone deficiency of hypothalamic origin
  3. 03HumanObservational studyEfficacy outcome

    In two of seven children with GH deficiency, growth rate rose during GHRH treatment, from 1.9 to 3.8 cm/year in one and from 3.5 to 8.2 cm/year in the other, which then fell to 5.4 cm/year.

    In plain wordsIn two of seven children with growth hormone deficiency, growth sped up on GHRH; in one it later slowed again.

    Peptide
    Sermorelin
    Outcome
    IncreaseGrowth rate on continuous s.c. GHRH (two responders)
    Study

    n = 2

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4-6 micrograms/kg twice daily · subcutaneous · at least 6 monthsAs given in this study (human).

    Measurements

    Growth rate before
    1.9 cm/year
    patient 1
    Growth rate on GHRH
    3.8 cm/year
    patient 1
    Growth rate before
    3.5 cm/year
    patient 2
    Growth rate on GHRH
    8.2 cm/year
    patient 2
    Later growth rate
    5.4 cm/year
    patient 2

    Source sentences

    Summary
    One patient increased his growth rate from 1.9 to 3.8 cm/year and another from 3.5 to 8.2 cm/year; however, the growth rate of the latter patient then decreased to 5.4 cm/year.
    1 context sentence
    Summary · context
    Seven children with growth hormone deficiency of hypothalamic origin

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.